A first attempt in this direction was made by Fereyoduni et al., who exploited MCs pre-sensitized with HER2/neu-specific IgE to efficiently kill HER2/neu-expressing tumor cells both in vitro and in vivo in a breast cancer model. Here, ERBB2 is linked to breast cancer.